keyword
MENU ▼
Read by QxMD icon Read
search

Bimatoprost

keyword
https://www.readbyqxmd.com/read/28176172/evaluation-of-retinal-ganglion-cell-function-after-intraocular-pressure-reduction-measured-by-pattern-electroretinogram-in-patients-with-primary-open-angle-glaucoma
#1
Joanna Karaśkiewicz, Krzysztof Penkala, Maciej Mularczyk, Wojciech Lubiński
BACKGROUND: To evaluate retinal ganglion cell (RGC) function after intraocular pressure (IOP) reduction measured by pattern electroretinogram (PERG) in patients with newly diagnosed, non-treated preperimetric and early stages of primary open-angle glaucoma (POAG). METHODS: Twenty-four eyes from 24 patients with POAG: 11 eyes with preperimetric glaucoma and 13 eyes with early glaucoma received Ganfort (®) (bimatoprost + timolol) once a day for a period of 1 month...
February 7, 2017: Documenta Ophthalmologica. Advances in Ophthalmology
https://www.readbyqxmd.com/read/28165835/assessment-of-the-anterior-chamber-flare-and-macular-thickness-in-patients-treated-with-topical-antiglaucomatous-drugs
#2
Fırat Selen, Oya Tekeli, Özge Yanık
PURPOSE: To determine the changes in the anterior chamber flare and central macular thickness (CMT) under topical antiglaucomatous therapy. METHODS: This study included 121 eyes of 73 patients and 36 eyes of 18 controls. Glaucoma patients were divided into 3 groups (timolol maleate, latanoprost, and bimatoprost). Control eyes did not receive any medications. Flare and CMT measurements were performed at baseline and follow-up visits (15th day, and 1st, 3rd, 6th, and 12th month)...
February 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28151873/bimatoprost-induced-late-onset-choroidal-detachment-after-trabeculectomy-a-case-report-and-review-of-the-literature
#3
Shunsuke Nakakura, Asuka Noguchi, Hitoshi Tabuchi, Yoshiaki Kiuchi
BACKGROUND: Choroidal detachment (CD) is often observed at an early period particularly after trabeculectomy and glaucoma drainage implant surgery. However, topical antiglaucoma eye drop-induced CD is a rare complication. Here, we report a case of topical bimatoprost-induced late-onset CD after trabeculectomy and review the literature. CASE REPORT: A 74-year-old man who suffered from primary open-angle glaucoma underwent his initial trabeculectomy with mitomycin-C in the right eye...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28146132/a-novel-convergent-synthesis-of-the-potent-antiglaucoma-agent-tafluprost
#4
Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17...
January 31, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28122407/effects-of-latisse-bimatoprost-0-03-per-cent-topical-solution-on-the-ocular-surface
#5
Etty Bitton, Claudine Courey, Pamela Giancola, Vasile Diaconu, Jack Wise, Walter Wittich
PURPOSE: LATISSE is marketed for the treatment of hypotrichosis (loss of eyelashes), using a prostamide analogue and preserved with benzalkonium chloride, which is an effective preservative; however, it also causes irritation to the ocular surface. LATISSE is applied to the lid margin; however, with the blink, some solution may fall onto the ocular surface. The objective of this study was to assess the effects of LATISSE on the ocular surface over two months. METHODS: Non-dry eye participants interested in eyelash lengthening were invited to a prospective uncontrolled, open-label clinical study using LATISSE for two months...
January 25, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/28053501/fixed-combination-of-travoprost-and-timolol-maleate-reduces-intraocular-pressure-in-japanese-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-analysis-by-prostaglandin-analogue
#6
Tadashi Nakano, Shiro Mizoue, Nobuo Fuse, Aiko Iwase, Shun Matsumoto, Keiji Yoshikawa
BACKGROUND: We have shown a decrease in mean intraocular pressure (IOP) by switching to travoprost/timolol fixed combination (TTFC) in subjects receiving prostaglandin analogue (PGA) monotherapy and requiring additional medication in a previous report. For analyzing factors affecting IOP reduction, baseline IOP and preceding PGA were selected as statistically and clinically significant factors. In this report, we examine IOP-lowering effect and adverse drug reactions by preceding PGA...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28012819/bimatoprost-sustained-release-implants-for-glaucoma-therapy-6-month-results-from-a-phase-i-ii-clinical-trial
#7
Richard A Lewis, William C Christie, Douglas G Day, E Randy Craven, Thomas Walters, Marina Bejanian, Susan S Lee, Margot L Goodkin, Jane Zhang, Scott M Whitcup, Michael R Robinson
PURPOSE: To evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost sustained-release implant (Bimatoprost SR). DESIGN: Phase I/II, prospective, 24-month, dose-ranging, paired-eye controlled clinical trial. METHODS: At baseline following washout, open-angle glaucoma patients (n=75) were administered Bimatoprost SR (6-μg, 10-μg, 15-μg, or 20-μg) intracamerally in the study eye; the fellow eye began topical bimatoprost 0...
December 21, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27994439/impact-of-prostaglandin-glaucoma-drops-on-platelet-activating-factor-action-an-in-vitro-study
#8
Marilita M Moschos, Eirini Nitoda, Irini P Chatziralli, Georgios D Panos, Constantinos A Demopoulos
AIM: The aim of this study was to investigate the effect of different prostaglandin analogs on platelet-activating factor (PAF) levels. METHODS: Three prostaglandin analogs were selected: bimatoprost 0.3 mg/mL, latanoprost 50 μg/mL, and tafluprost 15 μg/mL. Each drug sample was tested for its ability to cause platelet aggregation, which was measured as PAF-induced aggregation, before and after the addition of various concentrations of the examined sample, creating a linear curve of percentage inhibition (ranging from 0% to 100%) versus different concentrations of the sample...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27957367/bimatoprost-induced-serous-macular-detachment-after-cataract-surgery
#9
Swapnil Parchand, Subashini Kaliaperumal, Amit Kumar Deb, K Ramesh Babu, Renuka Srinivasan
We report a case of bimatoprost induced serous macular detachment and choroidal folds following uneventful cataract surgery. A 66-year-old male using topical bimatoprost in both eyes for open angle glaucoma underwent uneventful cataract surgery in the right eye. Postoperatively, he was restarted on topical bimatoprost and antibiotic-steroids combination drops. One week after surgery, he presented with conjunctival hyperemia, serous macular detachment, and choroidal folds at the posterior pole. Fundus fluorescein angiography showed perifoveal leaks in early stage with pooling of dye in late stage...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27906815/structural-and-histologic-eyelid-changes-associated-with-6-months-of-topical-bimatoprost-in-the-rabbit
#10
Tiffany L Kent, Philip L Custer
PURPOSE: To determine the periorbital effects of daily 0.03% bimatoprost in New Zealand white (NZW) rabbits. MATERIALS AND METHODS: NZW rabbits were treated with daily 0.03% bimatoprost, artificial tears, or left untreated. Following 3 and 6 months of treatment, eyelid measurements were obtained for both upper and lower eyelid distraction, as well as canthus-to-canthus measurements. Once complete, subjects were humanely euthanized and eyelid tissue was utilized for histology...
November 30, 2016: Journal of Glaucoma
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#11
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27770310/treating-alopecia-areata-current-practices-versus-new-directions
#12
REVIEW
Aditya K Gupta, Jessie Carviel, William Abramovits
Alopecia areata (AA) is non-scarring hair loss resulting from an autoimmune disorder. Severity varies from patchy hair loss that often spontaneously resolves to severe and chronic cases that can progress to total loss of scalp and body hair. Many treatments are available; however, the efficacy of these treatments has not been confirmed, especially in severe cases, and relapse rates are high. First-line treatment often includes corticosteroids such as intralesional or topical steroids for mild cases and systemic steroids or topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester in severe cases...
February 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/27764023/sustained-drug-delivery-for-glaucoma-current-data-and-future-trends
#13
Ahmad A Aref
PURPOSE OF REVIEW: Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. RECENT FINDINGS: Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and travoprost intraocular implants, as well as several other therapies in earlier stages of development...
March 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27703324/preservative-free-bimatoprost-0-03-timolol-0-5-fixed-combination-in-patients-with-glaucoma-in-clinical-practice
#14
Stefan Pfennigsdorf, Peter Eschstruth, Stefan Häsemeyer, Cord Feuerhake, Gerrett Brief, Ioana Grobeiu, Andrew Shirlaw
PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting. PATIENTS AND METHODS: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27672307/preservative-free-bimatoprost-0-03-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-in-clinical-practice
#15
Lutz E Pillunat, Peter Eschstruth, Stefan Häsemeyer, Ulrich Thelen, Christian Foja, Richard Leaback, Stefan Pfennigsdorf
BACKGROUND: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting. METHODS: This open-label study observed patients who were switched to PF bimatoprost 0...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27633513/tolerability-and-efficacy-of-bimatoprost-0-01%C3%A2-in-patients-with-open-angle-glaucoma-or-ocular-hypertension-evaluated-in-the-taiwanese-clinical-setting-the-asia-pacific-patterns-from-early-access-of-lumigan-0-01%C3%A2-appeal-taiwan-study
#16
MULTICENTER STUDY
Ying Ying Chen, Tsing-Hong Wang, Catherine Liu, Kwou-Yeung Wu, Shin-Lin Chiu, Susan Simonyi, Da-Wen Lu
BACKGROUND: In randomized, controlled trials of open-angle glaucoma (OAG) or ocular hypertension (OHT), bimatoprost 0.01 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.03 %. Given geographic/racial differences in glaucoma presentation, the APPEAL study assessed the occurrence and severity of hyperemia produced by bimatoprost 0.01 %, and its efficacy, in the Taiwanese clinical setting. METHODS: In this multicenter, open-label, observational study, treatment-naïve and previously treated patients with OHT or OAG received once-daily bimatoprost 0...
September 15, 2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27552406/do-cyclosporine-a-an-il-1-receptor-antagonist-uridine-triphosphate-rebamipide-and-or-bimatoprost-regulate-human-meibomian-gland-epithelial-cells
#17
Wendy R Kam, Yang Liu, Juan Ding, David A Sullivan
PURPOSE: Researchers have hypothesized that treatment with cyclosporine A (CyA), interleukin-1 receptor antagonists (IL-1RA; e.g., anakinra), P2Y2 receptor agonists (e.g., uridine triphosphate; UTP), and rebamipide may alleviate human meibomian gland dysfunction (MGD) and/or dry eye disease. Investigators have also proposed that prostaglandin analogues (e.g., bimatoprost) may induce MGD. Our goal was to determine whether these compounds directly influence human meibomian gland epithelial cell (HMGEC) function...
August 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27550870/efficacy-of-bimatoprost-in-the-treatment-of-non-facial-vitiligo
#18
Nooshin Bagherani, Bruce R Smoller
No abstract text is available yet for this article.
August 23, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27506567/does-the-intraocular-pressure-lowering-effect-of-prostaglandin-analogues-continue-over-the-long-term
#19
Caner Kara, Emine Malkoç Şen, Kadriye Ufuk Elgin, Kurtuluş Serdar, Pelin Yilmazbaş
The purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41...
August 9, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27377163/successful-treatment-of-pediatric-alopecia-areata-of-the-scalp-using-topical-bimatoprost
#20
Alvin W Li, Richard J Antaya
Alopecia areata (AA) is a genetic and immune-mediated disease that targets anagen hair follicles. Despite limited evidence supporting the efficacy of corticosteroid treatments, they are often prescribed as first-line therapy because of their favorable safety profile. Prostaglandin analogues are currently being studied as an alternate therapy for scalp AA in adults. Herein we present a case of steroid-resistant multifocal AA that was successfully treated with topical bimatoprost.
September 2016: Pediatric Dermatology
keyword
keyword
27282
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"